Innovators in Parkin Therapeutics
At NysnoBio we are dedicated to developing the therapeutic potential of the Parkin protein for patients with serious medical conditions. We envision a future where the power of the Parkin pathway is directed toward specific disease areas, where the activation of the repair pathway can have maximum therapeutic benefits. Our core team of industry professionals and network of academic experts are working together to deliver on on the scope of therapeutic potential for Parkin cellular repair.
LEADERSHIP
Jennifer A. Johnston, Ph.D.
Cofounder and CEO
David M. Weiner, M.D.
Chief Medical Officer
Susan Goelz, Ph.D.
Director of Clinical Endpoints
Ron Mandel, Ph.D.
Head of Gene Therapy Programs
Sarah Finley
Project Management
David Giannini
Cofounder and Executive Chairman
SCIENTIFIC ADVISORY BOARD
Deniz Kirik, M.D., Ph.D.
Professor of Neuroscience at Faculty of Medicine, Lund University, Sweden
Dr. Andres M. Lozano, OC, M.D., Ph.D., FRCSC, FRSC, FCAHS
Neurosurgeon, Krembil Neuroscience Centre, University Health Network /
University Professor and Chairman of Neurosurgery, University of Toronto
Eugene M. Johnson, Jr., Ph.D.
Professor Emeritus, Neurology and Developmental Biology, Washington University Medical School, St. Louis, Missouri
Professor Nobutaka Hattori Chairman and Professor of Neurology, and Dean of Faculty of Medicine, Juntendo University Tokyo
Professor J. William Langston
Clinical Professor, Department of Neurology & Neurological Sciences, Stanford University